Literature DB >> 14655810

Primary immunodeficiencies.

Megan A Cooper1, Thomas L Pommering, Katalin Korányi.   

Abstract

Primary immunodeficiencies include a variety of disorders that render patients more susceptible to infections. If left untreated, these infections may be fatal. The disorders constitute a spectrum of more than 80 innate defects in the body's immune system. Primary immunodeficiencies generally are considered to be relatively uncommon. There may be as many as 500,000 cases in the United States, of which about 50,000 cases are diagnosed each year. Common primary immunodeficiencies include disorders of humoral immunity (affecting B-cell differentiation or antibody production), T-cell defects and combined B- and T-cell defects, phagocytic disorders, and complement deficiencies. Major indications of these disorders include multiple infections despite aggressive treatment, infections with unusual or opportunistic organisms, failure to thrive or poor growth, and a positive family history. Early recognition and diagnosis can alter the course of primary immunodeficiencies significantly and have a positive effect on patient outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14655810

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  20 in total

1.  Impact of a physician education and patient awareness campaign on the diagnosis and management of primary immunodeficiencies.

Authors:  Diana Pickett; Vicki Modell; Ian Leighton; Fred Modell
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

2.  Immune globulin subcutaneous (human) vivaglobin: for the treatment of primary immunodeficiency diseases.

Authors: 
Journal:  P T       Date:  2009-06

3.  An immune globulin intravenous (human), 10% liquid privigen: for the treatment of primary immunodeficiency diseases.

Authors: 
Journal:  P T       Date:  2009-06

4.  Immune globulin intravenous (human), 5% liquid gammaplex: for replacement therapy of primary humoral immunodeficiency.

Authors: 
Journal:  P T       Date:  2011-06

5.  Privigen immune globulin intravenous (human), 10% liquid.

Authors: 
Journal:  P T       Date:  2011-08

6.  Global study of primary immunodeficiency diseases (PI)--diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation.

Authors:  Vicki Modell; Bonnie Gee; David B Lewis; Jordan S Orange; Chaim M Roifman; John M Routes; Ricardo U Sorensen; Luigi D Notarangelo; Fred Modell
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

7.  Comparative Study of Two ELISA Kits for Estimation of Antibodies to Hepatitis B Virus in Human Normal Immunoglobulin and Specific Immunoglobulin Intended for Intravenous or Intramuscular Use.

Authors:  J P Prasad; Y Madhu; Arushi Mandhan; Payal Garg; Anu Prakash; Varsha Singh; Daud Ali; Prdeep Kumar; Surinder Singh; G R Soni; Varun Singh
Journal:  Indian J Clin Biochem       Date:  2016-06-29

8.  Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement.

Authors:  Vicki Modell; Jessica Quinn; Grant Ginsberg; Ron Gladue; Jordan Orange; Fred Modell
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

9.  From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of primary immunodeficiencies.

Authors:  Fred Modell; Diana Puente; Vicki Modell
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

10.  Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network.

Authors:  Vicki Modell; Jessica Quinn; Jordan Orange; Luigi D Notarangelo; Fred Modell
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.